Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBP) Debt Ratio (2016 - 2024)

Regen BioPharma (RGBP) has disclosed Debt Ratio for 9 consecutive years, with 4.7 as the latest value for Q2 2024.

  • On a quarterly basis, Debt Ratio rose 570.58% to 4.7 in Q2 2024 year-over-year; TTM through Jun 2024 was 4.7, a 570.58% increase, with the full-year FY2023 number at 0.99, down 25.16% from a year prior.
  • Debt Ratio was 4.7 for Q2 2024 at Regen BioPharma, up from 3.86 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 5.98 in Q4 2023 to a low of 0.0 in Q4 2021.
  • A 5-year average of 1.31 and a median of 0.82 in 2022 define the central range for Debt Ratio.
  • Peak YoY movement for Debt Ratio: crashed 98.44% in 2021, then surged 10653.95% in 2022.
  • Regen BioPharma's Debt Ratio stood at 0.27 in 2020, then plummeted by 98.44% to 0.0 in 2021, then surged by 10653.95% to 0.45 in 2022, then surged by 1241.37% to 5.98 in 2023, then fell by 21.36% to 4.7 in 2024.
  • Per Business Quant, the three most recent readings for RGBP's Debt Ratio are 4.7 (Q2 2024), 3.86 (Q1 2024), and 5.98 (Q4 2023).